From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center


386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Last Updated: Thursday, December 28, 2023

According to research from the phase 3 TULIP trial—presented during the 2023 ESMO Congress—treatment with the HER2-targeting antibody-drug conjugate trastuzumab duocarmazine (T-Duo) confirmed a trend toward a numerically prolonged OS among patients with pretreated metastatic HER2-positive breast cancer, compared with patients treated with physician’s choice (PC; trastuzumab combined with capecitabine or vinorelbine or eribulin or lapatinib plus capecitabine). Median OS was 21.0 months and 19.5 months T-Duo and PC groups, respectively (HR 0.87 [95% CI: 0.68, 1.12]; P=0.236).

ESMO Congress 2023 Abstract
News & Literature Highlights

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review